• Je něco špatně v tomto záznamu ?

Fibroblast activation protein as a potential theranostic target in brain metastases of diverse solid tumours

M. Zubaľ, B. Výmolová, I. Matrasová, P. Výmola, J. Vepřková, M. Syrůček, R. Tomáš, Z. Vaníčková, E. Křepela, D. Konečná, P. Bušek, A. Šedo

. 2023 ; 55 (6) : 806-817. [pub] 20230616

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23016133

Brain metastases are a very common and serious complication of oncological diseases. Despite the vast progress in multimodality treatment, brain metastases significantly decrease the quality of life and prognosis of patients. Therefore, identifying new targets in the microenvironment of brain metastases is desirable. Fibroblast activation protein (FAP) is a transmembrane serine protease typically expressed in tumour-associated stromal cells. Due to its characteristic presence in the tumour microenvironment, FAP represents an attractive theranostic target in oncology. However, there is little information on FAP expression in brain metastases. In this study, we quantified FAP expression in samples of brain metastases of various primary origin and characterised FAP-expressing cells. We have shown that FAP expression is significantly higher in brain metastases in comparison to non-tumorous brain tissues, both at the protein and enzymatic activity levels. FAP immunopositivity was localised in regions rich in collagen and containing blood vessels. We have further shown that FAP is predominantly confined to stromal cells expressing markers typical of cancer-associated fibroblasts (CAFs). We have also observed FAP immunopositivity on tumour cells in a portion of brain metastases, mainly originating from melanoma, lung, breast, and renal cancer, and sarcoma. There were no significant differences in the quantity of FAP protein, enzymatic activity, and FAP+ stromal cells among brain metastasis samples of various origins, suggesting that there is no association of FAP expression and/or presence of FAP+ stromal cells with the histological type of brain metastases. In summary, we are the first to establish the expression of FAP and characterise FAP-expressing cells in the microenvironment of brain metastases. The frequent upregulation of FAP and its presence on both stromal and tumour cells support the use of FAP as a promising theranostic target in brain metastases.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016133
003      
CZ-PrNML
005      
20240305122109.0
007      
ta
008      
231013s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.pathol.2023.05.003 $2 doi
035    __
$a (PubMed)37419841
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Zubaľ, Michal $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic
245    10
$a Fibroblast activation protein as a potential theranostic target in brain metastases of diverse solid tumours / $c M. Zubaľ, B. Výmolová, I. Matrasová, P. Výmola, J. Vepřková, M. Syrůček, R. Tomáš, Z. Vaníčková, E. Křepela, D. Konečná, P. Bušek, A. Šedo
520    9_
$a Brain metastases are a very common and serious complication of oncological diseases. Despite the vast progress in multimodality treatment, brain metastases significantly decrease the quality of life and prognosis of patients. Therefore, identifying new targets in the microenvironment of brain metastases is desirable. Fibroblast activation protein (FAP) is a transmembrane serine protease typically expressed in tumour-associated stromal cells. Due to its characteristic presence in the tumour microenvironment, FAP represents an attractive theranostic target in oncology. However, there is little information on FAP expression in brain metastases. In this study, we quantified FAP expression in samples of brain metastases of various primary origin and characterised FAP-expressing cells. We have shown that FAP expression is significantly higher in brain metastases in comparison to non-tumorous brain tissues, both at the protein and enzymatic activity levels. FAP immunopositivity was localised in regions rich in collagen and containing blood vessels. We have further shown that FAP is predominantly confined to stromal cells expressing markers typical of cancer-associated fibroblasts (CAFs). We have also observed FAP immunopositivity on tumour cells in a portion of brain metastases, mainly originating from melanoma, lung, breast, and renal cancer, and sarcoma. There were no significant differences in the quantity of FAP protein, enzymatic activity, and FAP+ stromal cells among brain metastasis samples of various origins, suggesting that there is no association of FAP expression and/or presence of FAP+ stromal cells with the histological type of brain metastases. In summary, we are the first to establish the expression of FAP and characterise FAP-expressing cells in the microenvironment of brain metastases. The frequent upregulation of FAP and its presence on both stromal and tumour cells support the use of FAP as a promising theranostic target in brain metastases.
650    _2
$a lidé $7 D006801
650    _2
$a membránové proteiny $x metabolismus $7 D008565
650    _2
$a individualizovaná medicína $7 D057285
650    _2
$a kvalita života $7 D011788
650    _2
$a fibroblasty $x patologie $7 D005347
650    _2
$a serinové endopeptidasy $x metabolismus $7 D012697
650    12
$a karcinom z renálních buněk $x patologie $7 D002292
650    12
$a nádory mozku $x patologie $7 D001932
650    12
$a nádory ledvin $x patologie $7 D007680
650    _2
$a nádorové mikroprostředí $7 D059016
655    _2
$a časopisecké články $7 D016428
700    1_
$a Výmolová, Barbora $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic $7 xx0314709
700    1_
$a Matrasová, Ivana $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Výmola, Petr, $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic $d 1994- $7 xx0314736
700    1_
$a Vepřková, Jana $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Syrůček, Martin $u Department of Pathology, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Tomáš, Robert $u Department of Neurosurgery, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Vaníčková, Zdislava $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Křepela, Evžen $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Konečná, Dora $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic; Departments of Neurosurgery and Neurooncology, First Faculty of Medicine, Charles University and Military University Hospital, Prague, Czech Republic
700    1_
$a Bušek, Petr $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: petr.busek2@lf1.cuni.cz
700    1_
$a Šedo, Aleksi $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00003708 $t Pathology $x 1465-3931 $g Roč. 55, č. 6 (2023), s. 806-817
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37419841 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20240305122106 $b ABA008
999    __
$a ok $b bmc $g 1999950 $s 1202495
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 55 $c 6 $d 806-817 $e 20230616 $i 1465-3931 $m Pathology $n Pathology $x MED00003708
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...